IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow

in CHF 1 000

 

Notes

 

01.01.–30.09.2022

 

01.01.–30.09.2021

Cash flows from operating activities

 

 

 

 

 

 

Proceeds from sales of securities

 

4

 

455 156

 

846 534

Purchase of securities

 

4

 

(129 226)

 

(795 084)

Payments for services

 

 

 

(34 407)

 

(44 699)

Income taxes paid

 

 

 

(97)

 

(112)

Total cash flows from operating activities

 

 

 

291 426

 

6 639

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Dividend

 

 

 

(212 242)

 

(199 440)

Proceeds from sales of treasury shares

 

6

 

 

9 653

Purchase of treasury shares

 

6

 

(27 303)

 

(5 622)

Borrowing/(repayment) of bank loans

 

5

 

(52 000)

 

185 000

Interest payments

 

 

 

(949)

 

(648)

Total cash flows from financing activities

 

 

 

(292 494)

 

(11 057)

 

 

 

 

 

 

 

Foreign exchange difference

 

 

 

1 258

 

(623)

Change in cash and cash equivalents

 

 

 

190

 

(5 041)

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of the period

 

 

 

2 835

 

6 816

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the period

 

 

 

3 025

 

1 775

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer